BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-i Treatment Due to couGH in Slovakia

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)

First Posted Date: 2010-10-08

Last Posted Date: 2012-11-16

Lead Sponsor: Bayer

Target Recruit Count: 980

Registration Number: NCT01217879

Real Life Safety and Efficacy of Vardenafil

Terminated

Conditions: Erectile Dysfunction

Interventions: Drug: Vardenafil (Levitra, BAY38-9456)

First Posted Date: 2010-10-06

Last Posted Date: 2014-05-19

Lead Sponsor: Bayer

Target Recruit Count: 372

Registration Number: NCT01215409

Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation (Protocol P07515)

Phase 2

Completed

Conditions: Constipation

Interventions: Drug: PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)

First Posted Date: 2010-09-30

Last Posted Date: 2016-03-15

Lead Sponsor: Bayer

Target Recruit Count: 154

Registration Number: NCT01212445

COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-I Treatment Due to couGH in Poland

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)

First Posted Date: 2010-09-29

Last Posted Date: 2014-02-13

Lead Sponsor: Bayer

Target Recruit Count: 2498

Registration Number: NCT01211171

LEVITRA® Specific Drug Use Investigation. To Investigate the Safety Profile in Combination Use With Alpha-blockers

Completed

Conditions: Erectile Dysfunction

Interventions: Drug: Vardenafil (Levitra, BAY38-9456)

First Posted Date: 2010-09-23

Last Posted Date: 2015-01-21

Lead Sponsor: Bayer

Target Recruit Count: 491

Registration Number: NCT01207947

Dose-confirmatory Bridging Study in Total Knee Replacement

Phase 3

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: Rivaroxaban (BAY59-7939)
Drug: Enoxaparin

First Posted Date: 2010-09-22

Last Posted Date: 2017-01-18

Lead Sponsor: Bayer

Target Recruit Count: 302

Registration Number: NCT01206972

The Safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST)

Completed

Conditions: Angiocardiography

Interventions: Drug: Iopromide (Ultravist, BAY86-4877)

First Posted Date: 2010-09-21

Last Posted Date: 2013-06-11

Lead Sponsor: Bayer

Target Recruit Count: 17513

Registration Number: NCT01206257

Dose-confirmatory Bridging Study in Total Hip Replacement

Phase 3

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: Enoxaparin
Drug: Rivaroxaban (BAY59-7939)

First Posted Date: 2010-09-21

Last Posted Date: 2017-01-23

Lead Sponsor: Bayer

Target Recruit Count: 402

Registration Number: NCT01205932

Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.

Phase 2

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: BAY86-9766 MEK Inhibitor + Sorafenib

First Posted Date: 2010-09-17

Last Posted Date: 2013-09-06

Lead Sponsor: Bayer

Target Recruit Count: 70

Registration Number: NCT01204177

Investigation of Three Contraceptive Hormone Patches in Regard to Inhibition of Ovulation Following Application Over 3 Treatment Cycles in Healthy, Young Women.

Phase 2

Completed

Conditions: Contraception

Interventions: Drug: Gestodene/EE Patch (BAY86-5016)

First Posted Date: 2010-09-17

Last Posted Date: 2014-11-04

Lead Sponsor: Bayer

Target Recruit Count: 173

Registration Number: NCT01204190

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy